Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 259-262

  Hauck, Yolande ^a   Fabre, Michel ^b   Vergnaud, Gilles ^a   Soler, Charles ^b   Pourcel, Christine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b PERCY MILITARY HOSPITAL   (France)

Author keywords

Antibiotics; Hybridization; M. tuberculosis; Probes; Rifabutin

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HYBRIDIZATION; INTERMETHOD COMPARISON; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID HYBRIDIZATION; REAGENT KITS, DIAGNOSTIC; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 67650739479     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp204     Document Type: Article

References (10)

1. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-41.
2. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001; 2: 164-8.
3. Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-50.
4. Morgan M, Kalantri S, Flores L et al. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis. BMC Infect Dis 2005; 5: 62.
5. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-40.
6. Miotto P, Piana F, Cirillo DM et al. Genotype MTBDRplus: A further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2008; 46: 393-4.
7. Lacoma A, Garcia-Sierra N, Prat C et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008; 46: 3660-7.
8. Heep M, Brandstatter B, Rieger U et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001; 39: 107-10.
9. Kapur V, Li LL, Iordanescu S et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase β subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32: 1095-8.
10. Ma X, Wang H, Deng Y et al. rpoB gene mutations and molecular characterization of rifampin-resistant Mycobacterium tuberculosis isolates from Shandong Province, China. J Clin Microbiol 2006; 44: 3409-12.